Biogen vs H&M (Hennes & Mauritz)

Side-by-side comparison of AI visibility scores, market position, and capabilities

Biogen leads in AI visibility (91 vs 28)

Biogen

LeaderHealthcare Tech

Enterprise

Cambridge MA neuroscience biopharma (NASDAQ: BIIB) at $9.7B 2024 revenue; LEQEMBI $87M Q4 (Alzheimer's first-in-class amyloid therapy), SKYCLARYS $102M Q4 (Friedreich's ataxia), MS franchise declining vs. Eli Lilly donanemab.

AI VisibilityBeta
Overall Score
A91
Category Rank
#129 of 290
AI Consensus
84%
Trend
stable
Per Platform
ChatGPT
99
Perplexity
93
Gemini
96

About

Biogen Inc. is a Cambridge, Massachusetts-based neuroscience biopharmaceutical company — publicly traded on NASDAQ (NASDAQ: BIIB) as an S&P 500 Health Care component — researching, developing, and commercializing therapies for neurological, neurodegenerative, and neurodevelopmental diseases including Alzheimer's disease, multiple sclerosis, spinal muscular atrophy, and rare neurological conditions through approximately 7,400 employees worldwide. In fiscal year 2024, Biogen reported total revenue of $9.7 billion (-2% year-over-year) and GAAP diluted EPS of $11.18 (+40%), reflecting significant cost-cutting that improved profitability despite modest revenue decline. Revenue decline was driven by continued erosion in the core multiple sclerosis franchise (TECFIDERA, AVONEX, TYSABRI facing generic and biosimilar competition) while new product revenue grew: LEQEMBI (lecanemab, Alzheimer's disease, partnered with Eisai) generated approximately $87 million in Q4 2024 global sales — reflecting the slow but building commercial trajectory of the first drug to slow Alzheimer's cognitive decline — and SKYCLARYS (omaveloxolone, Friedreich's ataxia) generated $102 million in Q4, nearly double the year-earlier period. CEO Christopher Viehbacher, who joined in 2022 from Genentech's parent Roche, has led a strategic restructuring that includes cost reduction, pipeline refocus on high-probability neurology programs, and the LEQEMBI commercial execution through a partnership model with Eisai.

Full profile

H&M (Hennes & Mauritz)

Unknownretail

fashion retail

Global fast-fashion giant with 4,100+ stores across 78 markets. Q1 2026 revenue up 3%; investing in AI personalization and sustainability initiatives.

AI VisibilityBeta
Overall Score
D28
Category Rank
#270 of 1167
AI Consensus
53%
Trend
stable
Per Platform
ChatGPT
31
Perplexity
33
Gemini
21

About

H&M Hennes & Mauritz is a Swedish multinational fashion retailer founded in 1947, operating brands including H&M, COS, & Other Stories, ARKET, and Weekday. The company runs approximately 4,100 stores worldwide with annual revenue of ~$23B, generating 66% of sales from Europe.

Full profile

AI Visibility Head-to-Head

91
Overall Score
28
#129
Category Rank
#270
84
AI Consensus
53
stable
Trend
stable
99
ChatGPT
31
93
Perplexity
33
96
Gemini
21
99
Claude
39
95
Grok
21

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.